Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00332488 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

A Phase 3 study, sponsored by Mannkind Corporation.

Completed
Registry status
Phase 3
Development phase
547
Enrollment target

NCT00332488 is a Phase 3 study that has completed, run by Mannkind Corporation. The registered enrollment target is 547 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00332488, a Phase 3 study, has completed, sponsored by Mannkind Corporation.

COMPLETED
Registry status
Phase 3
Development phase
547 participants
Enrollment target

Study Summary

to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue

Interventions

  • DRUG Technosphere Insulin
  • DRUG Metformin & Secretagogues
  • DRUG Technosphere Insulin & Metformin

Trial Details

FieldValue
Enrollment Target 547 participants
Start Date 2004-12
Phase Phase 3

Sponsor

Mannkind Corporation

42 total trials

What the Registry Record Tells You About NCT00332488

The ClinicalTrials.gov registry entry for NCT00332488 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Technosphere Insulin is the first listed.

NCT00332488 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00332488 about?

NCT00332488 is a clinical study titled "Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes". to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue

What is the current status of trial NCT00332488?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2004-12.

What interventions are being tested in trial NCT00332488?

The interventions under investigation include: Technosphere Insulin (DRUG), Metformin & Secretagogues (DRUG), Technosphere Insulin & Metformin (DRUG).

Who is sponsoring clinical trial NCT00332488?

This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.